Osteolytic bone metastasis in breast cancer

1994 ◽  
Vol 32 (1) ◽  
pp. 73-84 ◽  
Author(s):  
Toshiyuki Yoneda ◽  
Akira Sasaki ◽  
Gregory R. Mundy
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

scholarly journals Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Jin Liu ◽  
Defang Li ◽  
Lei Dang ◽  
Chao Liang ◽  
Baosheng Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

scholarly journals Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer

2020 ◽  
Vol 61 (3) ◽  
pp. 494-498
Author(s):  
Hidekazu Tanaka ◽  
Chiyoko Makita ◽  
Yuki Manabe ◽  
Miki Kajima ◽  
Katsuya Matsuyama ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Progressive Disease ◽  
Overall Survival Rate ◽  
Local Response ◽  
Osteolytic Bone Metastasis ◽  
Rate Of Response

Abstract Bone-modifying agents (BMAs) are frequently used for the treatment of bone metastases. Both BMA and radiation therapy (RT) are effective; however, there are few studies that have evaluated the efficacy of the combination treatment. We evaluated the effectiveness of RT + BMA in breast cancer-induced osteolytic bone metastasis as compared to BMA alone. A total of 43 lesions in 25 patients were evaluated. The median follow-up period was 18 (range, 2–90) months. None of the lesions was treated with chemotherapy or molecular targeted drugs during the follow-up period for evaluating the local response. Patients with complete or partial response were considered as responders, while those with stable or progressive disease were considered as non-responders. The rate of response with RT + BMA was significantly higher than that with BMA alone (P = 0.001). The cumulative incidence rate of response at 6 months was 54.4% in the RT + BMA group and 27.5% in the BMA alone group. The median time to response was 4 (range, 2–11) months in the RT + BMA group and 6 (range, 4–16) months in the BMA alone group. The overall survival rate in the responder group (83.1% at 1 year) was significantly higher than that in the non-responder group (37.5% at 1 year) (P = 0.029). In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis.

Immunization With RANKL Inhibits Osteolytic Bone Metastasis in Breast Cancer

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bora Kim ◽  
Yong Jin Cho ◽  
Mineon Park ◽  
Wonbong Lim
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Osteolytic Bone Metastasis

NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF

2006 ◽  
Vol 13 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Bae Keun Park ◽  
Honglai Zhang ◽  
Qinghua Zeng ◽  
Jinlu Dai ◽  
Evan T Keller ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Osteolytic Bone Metastasis ◽  
Gm Csf

Abstract 1753: Comparison between early versus delayed treatment of breast cancer induced osteolytic bone metastasis by TGFβ inhibitors in a murine model

2011 ◽  
Author(s):  
Abhik Bandyopadhyay ◽  
Joseph Agyin ◽  
Fernando Lopez-Casillas ◽  
Long Wang ◽  
Tanuka Biswas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Murine Model ◽  
Osteolytic Bone Metastasis ◽  
Delayed Treatment

scholarly journals Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells

Cancer Cell ◽  
2011 ◽  
Vol 19 (2) ◽  
pp. 192-205 ◽  
Author(s):  
Nilay Sethi ◽  
Xudong Dai ◽  
Christopher G. Winter ◽  
Yibin Kang
Keyword(s):  
Breast Cancer ◽  
Bone Metastasis ◽  
Notch Signaling ◽  
Bone Cells ◽  
Osteolytic Bone Metastasis
Sign in / Sign up

Export Citation Format

Share Document